Billions Read more...

Investors in Agios Pharmaceuticals are facing a tense waiting period as a crucial regulatory verdict approaches. The U.S. Food and Drug Administration is set to announce its decision regarding the expanded use of the company’s flagship drug, PYRUKYND, within days?an outcome that could fundamentally reshape the biotech firm’s valuation. This high-stakes environment was further highlighted by recent quarterly earnings that revealed the stark contrast between the company’s promising pipeline and its current financial performance.